Thane, India

Kalpana Sanjay Joshi

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kalpana Sanjay Joshi: Innovator in Medicinal Chemistry

Introduction

Kalpana Sanjay Joshi is a notable inventor based in Thane, India. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds with anti-inflammatory and anti-cancer properties. With a total of 2 patents to her name, her work has garnered attention in the scientific community.

Latest Patents

Kalpana's latest patents include innovative compounds such as Arylcycloalkyl derivatives, which are produced for their use in treating inflammatory conditions. These compounds are characterized by specific substituents, R1-R4, as detailed in the specifications. Additionally, she has developed Esculentin A and Esculentin B, which are derived from plants in the Samydaceae family, particularly Casearia esculenta. These compounds are not only significant for their preparation processes but also for their applications in the manufacture of medicaments aimed at combating inflammation and cancer.

Career Highlights

Throughout her career, Kalpana has worked with prominent companies in the pharmaceutical industry, including Hoechst Aktiengesellschaft and Hoechst Marion Roussel Deutschland GmbH. Her experience in these organizations has allowed her to refine her expertise in medicinal chemistry and contribute to groundbreaking research.

Collaborations

Kalpana has collaborated with several professionals in her field, including Swati Bal-Tembe and Ramachandra Ganapati Naik. These collaborations have further enriched her research and development efforts.

Conclusion

Kalpana Sanjay Joshi's contributions to medicinal chemistry through her patents and collaborations highlight her role as an innovator in the field. Her work continues to impact the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…